Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) and Merck’s KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more
Publication date: Available online 22 February 2019Source: Chemico-Biological InteractionsAuthor(s): Saba Tabasum, Rana P. SinghAbstractFisetin (3,3′,4′,7-tetrahydroxyflavone) is a bioactive polyphenolic flavonoid found in many fruits and vegetables. It exhibits a variety of pharmacological activities including anticancer and anti-invasive effects. Epithelial to mesenchymal transition (EMT) allows the tumor to cells to acquire increased migratory and invasive properties mediating their dissemination to faraway sites, thus favoring metastasis. With metastatic lung cancer claiming the majority of lung cancer-rela...
To compare the overall survival (OS) after percutaneous image-guided ablation of stage T1 Non –small cell lung cancer (NSCLC) performed in cancer centers, academic institutions or community-based hospitals.
This study aimed to evaluat...
Background: Second primary malignancies (SPM) in the lung are not common in breast cancer (BC) patients.EGFR-mutant lung cancer (LC) is a separate molecular subset, and the co-existence ofEGFR-mutant LC and BC has not been explored. We hypothesized thatEGFR-mutant LC patients could have higher rates of primary BC than those withEGFR-wild type (WT).Methods: We collected data on clinical and molecular characteristics and outcomes of female patients with LC and a previous or simultaneous history of primary BC treated in our hospital from 2008 to 2014.Results: Data on treatment, follow-up, andEGFR mutation status were availabl...
ConclusionsMale gender, poor performance status, distant metastases and recent weight loss predict for poor overall survival (OS) in older patients with advanced NSCLC. This study proposes a simple prognostic model for older adults with advanced NSCLC.
Compared with standard radiotherapy, stereotactic ablative body radiotherapy (SABR) provides better local control and improved survival in patients with inoperable peripherally located stage 1 non-small-cell lung cancer (NSCLC), according to results of the CHISEL study.Reuters Health Information
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.
In conclusion, this meta-analysis suggested that elevated LDH level was associated with the poor PFS and OS of NSCLC patients receiving EGFR-TKIs treatment. PMID: 30782303 [PubMed - in process]
With the discovery of anaplastic lymphoma kinase (ALK) rearrangement (ALK+) in non-small cell lung cancer (NSCLC) in 2007 [1,2], and the successful development and approval of 5 structurally different ALK tyrosine kinase inhibitors (TKIs) in the US [3,4], ALK+ NSCLC has become the prototypic model for drug development in targeted therapy. Additionally, it is now recognized that receptor tyrosine kinase (RTK) rearrangement/fusion is a class of actionable de novo driver mutation in NSCLC and other solidi malignancies [5,6] and more recently as one category of acquired resistance mechanism to epidermal growth factor receptor (EGFR) TKIs .